Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1146

Shown on this page

Current sort

Live official records

Conditions: Breast Reconstruction
Interventions: Acellular Dermal Matrix (Cortiva Tissue Matrix); Device
Lead sponsor: RTI Surgical; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 7 more

Conditions: ISS, SGA
Interventions: Somatrogon, Genotropin; Drug
Lead sponsor: Rabin Medical Center; Other
Eligibility: 3 Years to 11 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Centennial, Colorado • Jacksonville, Florida + 9 more

Conditions: Colorectal Cancer Screening
Interventions: Educational Program; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 45 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Methylphenidate Hydrochloride Extended Release Capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Tarlatamab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more

Conditions: Smoking Cessation, Tobacco Use Cessation
Interventions: Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), Financial incentives for smoking cessation, Financial incentives for use of evidence-based smoking cessation therapies; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Clostridoides Difficile Associated Disease
Interventions: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 936 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more

Conditions: Systemic Lupus Erythematosus
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Interventions: Not listed
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2027
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York + 2 more

Conditions: Solid Tumors
Interventions: QTX3034, Cetuximab; Drug · Combination Product
Lead sponsor: Quanta Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

About this NYU Langone Health institution page

What this page lists: ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NYU Langone Health

Filter and sort this campus

Live official records

Acellular Dermal Matrix Investigation in Breast Reconstruction

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

Pilot Testing of a Colorectal Cancer Education Program

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Financial Incentives for Smoking Treatment II

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

QTX3034 in Patients With KRAS G12D Mutation

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

About this NYU Langone Health institution page